Pekin Hardy Strauss Inc. Sells 10,000 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Pekin Hardy Strauss Inc. lessened its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 39.7% in the third quarter, according to its most recent filing with the SEC. The firm owned 15,170 shares of the biotechnology company’s stock after selling 10,000 shares during the quarter. Pekin Hardy Strauss Inc.’s holdings in Heron Therapeutics were worth $30,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. Intech Investment Management LLC bought a new stake in shares of Heron Therapeutics during the third quarter valued at approximately $72,000. King Wealth Management Group increased its position in shares of Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 8,000 shares during the period. GSA Capital Partners LLP raised its position in shares of Heron Therapeutics by 18.4% in the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after buying an additional 79,680 shares in the last quarter. Principal Financial Group Inc. lifted its position in Heron Therapeutics by 456.5% during the third quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 84,205 shares during the last quarter. Finally, Cutter & CO Brokerage Inc. purchased a new position in shares of Heron Therapeutics during the 3rd quarter valued at about $39,000. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Price Performance

NASDAQ:HRTX opened at $1.14 on Tuesday. The firm has a market cap of $173.39 million, a PE ratio of -6.33 and a beta of 1.81. The company has a 50-day moving average of $1.74 and a 200 day moving average of $2.44. Heron Therapeutics, Inc. has a 1-year low of $1.04 and a 1-year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the previous year, the business earned ($0.17) earnings per share. Sell-side analysts anticipate that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on HRTX. Needham & Company LLC cut their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. StockNews.com downgraded shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 21st.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.